Clinical Trials | May 26, 2026
Lilly posts strong early clinical results for one-shot gene-editing cholesterol therapy
A one-shot gene-editing cholesterol therapy could soon be a reality
A one-shot gene-editing cholesterol therapy could soon be a reality
Fresh data from the State of the World’s Nursing 2025 report shows the global nursing workforce has expanded from 27.9 million in 2018 to 29.8 million in 2023
The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
With standout ADC and t-cell engager response data across hard-to-treat cancers
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
AI and analytics leader brings extensive expertise in machine learning, GenAI, and life sciences decision intelligence to Lilly’s data science operations
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
Subscribe To Our Newsletter & Stay Updated
